Generalized Anxiety Disorder Market Report 2026

The generalized anxiety disorder market size has grown steadily in recent years. It will grow from $7.93 billion in 2025 to $8.18 billion in 2026 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to growing mental health awareness, availability of antidepressants, expansion of psychiatric services, societal stress factors, primary care diagnosis.

The generalized anxiety disorder market size is expected to see steady growth in the next few years. It will grow to $9.72 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to growth in digital therapeutics, demand for personalized mental healthcare, increased telehealth adoption, focus on preventive mental health, innovation in neuromodulation therapies. Major trends in the forecast period include rising adoption of cognitive behavioral therapy, increased use of pharmacological anxiety treatments, growth of digital mental health platforms, expansion of remote and telepsychiatry services, increased awareness of mental health disorders.

The increasing prevalence of mental disorders is driving the growth of the generalized anxiety disorder market. Mental disorders, also referred to as mental illnesses, encompass a wide range of conditions that affect a person’s thoughts, emotions, behaviors, and overall mental well-being. Conditions commonly associated with generalized anxiety disorder include phobias, panic disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD). Effectively managing these disorders is essential for individuals to maintain healthy relationships and improve quality of life. For example, in November 2023, the Stress in America 2023 survey, published by the American Psychological Association, a US-based professional organization, reported that adults aged 35 to 44 experienced the highest increase in mental health diagnoses, with 45% reporting a mental illness in 2023 compared with 31% previously. However, adults aged 18 to 34 continued to report the highest overall rate of mental illnesses at 50% in 2023. Therefore, the growing number of mental disorder cases is expected to propel the generalized anxiety disorder market.

Key companies in the generalized anxiety disorder market are focusing on developing innovative drugs, such as MM-120, and securing approvals to better address patient needs. These drugs aim to improve the management and outcomes of generalized anxiety disorder. For instance, in September 2023, Mind Medicine Inc. (MindMed), a US-based biotech company specializing in psychedelic-inspired therapies, completed enrollment in its Phase 2b trial of MM-120 (lysergide D-tartrate) for generalized anxiety disorder (GAD). This milestone is intended to generate robust efficacy and safety data to support further development of MM-120 as a novel treatment for GAD. MM-120 is a small-molecule partial agonist of the 5-HT₂A receptor, designed to enhance neuroplasticity and serotonin signaling to improve mood and reduce anxiety, and it demonstrated a dose-dependent reduction in anxiety symptoms during the trial.

In July 2023, Big Health, a US-based digital therapeutics company, acquired Limbix Health Inc. for an undisclosed amount. Through this acquisition, Big Health aims to strategically combine expertise and resources with Limbix to develop and deliver more effective digital therapeutics for mental health conditions. Limbix Health Inc., a US-based digital therapeutics platform, provides mental health treatments for young people suffering from depression, anxiety, and other mental illnesses.

Major companies operating in the generalized anxiety disorder market are Alkermes plc, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Bristol-Myers Squibb, GlaxoSmithKline plc, Johnson And Johnson Private Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Mylan N.V., Sumitomo Pharma Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Neurocrine Biosciences Inc., Actavis Pharmaceutical Company, Eli Lilly and Company, Mind Medicine Inc., Sage Therapeutics Inc., VistaGen Therapeutics Inc.

North America was the largest region in the generalized anxiety disorder market in 2025. The regions covered in the generalized anxiety disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generalized anxiety disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the generalized anxiety disorder market by increasing costs of imported psychiatric medications, medical devices, and therapy equipment. Hospitals and specialty clinics are most affected due to reliance on imported treatments. These tariffs raise treatment costs by increasing pricing for long-term pharmacotherapy and supportive treatment tools, potentially affecting patient access and adherence. However, they support domestic pharmaceutical manufacturing, promoting local production of psychiatric medications and reducing dependence on imported drugs.

The generalized anxiety disorder market research report is one of a series of new reports that provides generalized anxiety disorder market statistics, including generalized anxiety disorder industry global market size, regional shares, competitors with a generalized anxiety disorder market share, detailed generalized anxiety disorder market segments, market trends and opportunities, and any further data you may need to thrive in the generalized anxiety disorder industry. This generalized anxiety disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generalized anxiety disorder (GAD) is a mental health condition marked by excessive and persistent worry, fear, and anxiety about various aspects of life. It involves a wide range of concerns that can often feel uncontrollable and overwhelming. Treatment approaches vary depending on how significantly GAD affects a person’s daily functioning.

The main types of generalized anxiety disorder include panic disorder, agoraphobia, generalized anxiety, social anxiety, specific phobia, and others. Panic disorder is a mental health condition characterized by recurring and unexpected episodes of intense fear and discomfort, known as panic attacks. Treatment options include therapies such as interpersonal therapy, behavior therapy, cognitive behavioral therapy, and mindfulness-based cognitive therapy, along with the use of devices such as deep brain stimulation, electroconvulsive therapy, transcranial magnetic stimulation, and vagus nerve stimulation. These treatments are provided by hospitals, homecare services, specialty clinics, and others.

The generalized anxiety disorder market consists of revenues earned by entities by providing services such as exposure therapy, supportive psychotherapy, relaxation therapies, group therapy, stress management and self-care practices. The market value includes the value of related goods sold by the service provider or included within the service offering. The generalized anxiety disorder market also includes sales of pregabalin, hydroxyzine, beta-blockers, atypical antipsychotics and alprazolam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.